Retatrutide: difference between revisions
Diff·revision 13 → 14·01:47, 21 Nov 2024
Difference between revision 13 and revision 14 of Retatrutide. 5 lines changed; the page grew by 404 bytes.
| Revision 13 — 04:30, 5 Nov 2024 CagriCass (talk) correct the dose ladder — the maintenance dose is not the maximum dose 4,077 bytes +170 | Revision 14 — 01:47, 21 Nov 2024 AppendixAlva (talk) rm the equipotency claim — the cited paper does not make it 4,481 bytes +404 | ||
|---|---|---|---|
| 12 | | Residues = 39 | 12 | | Residues = 39 |
| 13 | | Molar mass = ≈4,731 g·mol⁻¹ | 13 | | Molar mass = ≈4,731 g·mol⁻¹ |
| + | 14 | <!-- Pharmacokinetics --> | |
| + | 15 | | Half-life = ≈6 days | |
| + | 16 | | Route = Subcutaneous, weekly | |
| 14 | }} | 17 | }} |
| 15 | {{hatnote|Retatrutide is investigational and is not approved for use in any indication. For the two-receptor case, see [[Tirzepatide]].}} | 18 | {{hatnote|Retatrutide is investigational and is not approved for use in any indication. For the two-receptor case, see [[Tirzepatide]].}} |
| ⋮ | ⋮ | ||
| 38 | | 8 mg | −22.8% | | 41 | | 8 mg | −22.8% | |
| 39 | | 12 mg | −24.2% | | 42 | | 12 mg | −24.2% | |
| + | 43 | ||
| + | 44 | The weight-change curve had not clearly plateaued by 48 weeks at the higher doses, which is unusual in this field and is one reason the phase 3 programme extends further.{{r|jastreboff2023}} A separate phase 2 trial in type 2 diabetes reported glycated-haemoglobin reductions of up to about 2.0 percentage points. | |
| 40 | 45 | ||
| 41 | == References == | 46 | == References == |